Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

被引：14

作者：

Chanthavanich, Pornthep ^{[1
]}

Limkittikul, Kriengsak ^{[1
]}

Sirivichayakul, Chukiat ^{[1
]}

Chokejindachai, Watcharee ^{[1
]}

Hattasingh, Weerawan ^{[1
]}

Pengsaa, Krisana ^{[1
]}

Surangsrirat, Surachai ^{[2
]}

Srisuwannaporn, Termsang ^{[2
]}

Kaewma, Benjawan ^{[2
]}

Yoksan, Sutee ^{[3
]}

Jun, Gao ^{[4
]}

Zhumu, Bai ^{[4
]}

机构：

[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, 420-6 Rajvithi Rd, Bangkok 10400, Thailand

[2] Nopparat Rajathanee Hosp, Minist Publ Hlth, Bangkok, Thailand

[3] Mahidol Univ, Inst Mol Biosci, Ctr Vaccine Dev, Japanese Encephalitis Dengue Virol Lab, Bangkok, Thailand

[4] Liaoning Cheng Da Biotechnol Co Ltd, Shenyang, Liaoning, Peoples R China

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期

关键词：

children; chromatographical purify; immunogenicity; Inactivated Vero cell-derived JE vaccine; pediatrics; safety; vaccinology; TRAVELERS;

D O I：

10.1080/21645515.2017.1414763

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7-28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions-fever (17.6%), vomiting (8%), and poor appetite (5.3%)-were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.

引用

页码：900 / 905

页数：6

共 50 条

[41] SAFETY PROFILE AND IMMUNOGENICITY OF AN INACTIVATED VACCINE DERIVED FROM AN ATTENUATED STRAIN OF HEPATITIS-A
ELLERBECK, EF
LEWIS, JA
NALIN, D
GERSHMAN, K
MILLER, WJ
ARMSTRONG, ME
DAVIDE, JP
RHOAD, AE
MCGUIRE, B
CALANDRA, G
PROVOST, PJ
MIDTHUN, K
VACCINE, 1992, 10 (10) : 668 - 672
[42] Immunogenicity & safety of a single dose of live-attenuated Japanese encephalitis vaccine SA 14-14-2 in adults
Khan, Siraj Ahmed
Kakati, Sanjeeb
Dutta, Prafulla
Chowdhury, Purvita
Borah, Jani
Topno, Rashmee
Jadhav, Santoshkumar M.
Mohapatra, Pradyumna K.
Mahanta, Jagadish
Gupte, Mohan D.
INDIAN JOURNAL OF MEDICAL RESEARCH, 2016, 144 : 886 - 892
[43] A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older
Essink, Brandon J.
Vermeulen, Wim
Andrade, Coralie
de Rooij, Richard
Isakov, Leah
Casula, Daniela
Albano, Frank R.
VACCINE, 2025, 51
[44] Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects
Shi, Nianmin
Zhang, Yibin
Zheng, Huizhen
Zhu, Zhenggang
Wang, Dingming
Li, Sihai
Li, Yuhua
Yang, Liqing
Zhang, Junnan
Bai, Yunhua
Lu, Qiang
Zhang, Zheng
Luo, Fengji
Yu, Chun
Li, Li
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (06) : 1338 - 1345
[45] A comparative study of the serological response to Japanese encephalitis vaccine in HIV-infected and uninfected Thai children
Chokephaibulkit, Kulkanya
Plipat, Nottasorn
Yoksan, Sutee
Phongsamart, Wanatpreeya
Lappra, Keswadee
Chearskul, Pimpanada
Chearskul, Sanay
Wittawatmongkol, Orasri
Vanprapar, Nirun
VACCINE, 2010, 28 (20) : 3563 - 3566
[46] Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children An Open-label, Randomized, Active-controlled, Phase 3 Study
Dubischar, Katrin L.
Kadlecek, Vera
Sablan, Benjamin, Jr.
Borja-Tabora, Charissa Fay
Gatchalian, Salvacion
Eder-Lingelbach, Susanne
Mueller, Zsuzsanna
Westritschnig, Kerstin
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (09) : 889 - 897
[47] Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children
Langley, Joanne M.
Carmona Martinez, Alfonso
Chatterjee, Archana
Halperin, Scott A.
McNeil, Shelly
Reisinger, Keith S.
Aggarwal, Naresh
Huang, Li-Min
Peng, Ching-Tien
Garcia-Sicilia, Jose
Salamanca de la Cueva, Ignacio
Cabanas, Fernando
Trevino-Garza, Consuelo
Angel Rodriguez-Weber, Miguel
de la O, Manuel
Chandrasekaran, Vijayalakshmi
Dewe, Walthere
Liu, Aixue
Innis, Bruce L.
Jain, Varsha K.
JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (04) : 544 - 553
[48] Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine
Wijesinghe, Pushpa Ranjan
Abeysinghe, M. R. Nihal
Yoksan, Sutee
Yao, Yafu
Zhou, Benli
Zhang, Lei
Fleming, Jessica A.
Marfin, Anthony A.
Victor, John C.
VACCINE, 2016, 34 (48) : 5923 - 5928
[49] Immunogenicity of a live-attenuated Japanese encephalitis vaccine in children and adolescents after hematopoietic stem cell transplantation
Pakakasama, S.
Wattanatitan, S.
Techasaensiri, C.
Yoksan, S.
Sirireung, S.
Hongeng, S.
BONE MARROW TRANSPLANTATION, 2014, 49 (10) : 1307 - 1309
[50] Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture-Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age
Vesikari, Timo
Block, Stan L.
Guerra, Fernando
Lattanzi, Maria
Holmes, Sandra
Izu, Allen
Gaitatzis, Nicolaos
Hilbert, Anne Katrin
Groth, Nicola
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (05) : 494 - 500

← 1 2 3 4 5 →